Innovative ATMP for rare diseases
Head: Lenka Zdražilová Dubská
Brno node
HOME INSTITUTION
Faculty of Medicine MU
RESEARCH PROGRAMME(S)
RP 5 - Translational oncology: Verification clinical studies of the proof-of-concept type
Innovative Therapy Requires Vision, Knowledge, and Common Sense.
- Mission: To develop advanced therapies for high-risk pediatric tumors and rare diseases by harnessing cutting-edge technologies in cancer research, gene editing, and cell engineering. We prioritize translational research, development, and production of advanced investigational medicinal products, delivering innovative solutions to pediatric and adult patients with unmet medical needs.
- Vision: To pioneer transformative advanced therapies that treat, and potentially cure, high-risk tumors and select rare diseases. By advancing gene editing and immune cell engineering, we strive to deliver precise, targeted treatments to our patients.
SELECTED PUBLICATIONS
- Kyr M, Mudry P, Polaskova K, Zdrazilova Dubska L, Demlova R, Kubatova J, Hlavackova E, Cerna Pilatova K, Mazanek P, Vejmelkova K, Dusek V, Tinka P, Balaz M, Merta T, Kuttnerova Z, Turekova T, Pavelka Z, Pokorna P, Palova H, Minarikova M, Jezova M, Kellnerova R, Kozakova S, Slaby O, Valik D, Sterba J. Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients. Int J Cancer. 2024 Oct 15;155(8):1443-1454. DOI: 10.1002/ijc.35062
- Bilek O, Holanek M, Jurica J, Stepankova S, Vasina J, Selingerova I, Poprach A, Borilova S, Kazda T, Kiss I, Zdrazilova-Dubska L. Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient. Int Immunopharmacol. 2021 Oct:99:108012. DOI: 10.1016/j.intimp.2021.108012
- Fedorova L, Mudry P, Pilatova K, Selingerova I, Merhautova J, Rehak Z, Valik D, Hlavackova E, Cerna D, Faberova L, Mazanek P, Pavelka Z, Demlova R, Sterba J, Zdrazilova-Dubska L. Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma. Front Oncol. 2019 Nov 14;9:1169. DOI: 10.3389/fonc.2019.01169
- Hlavackova E, Pilatova K, Cerna D, Selingerova I, Mudry P, Mazanek P, Fedorova L, Merhautova J, Jureckova L, Semerad L, Pacasova R, Flajsarova L, Souckova L, Demlova R, Sterba J, Valik D, Zdrazilova-Dubska L. Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behavior of DCs and Manufacturing Process Outcome. Front Oncol. 2019 Oct 25;9:1034. DOI: 10.3389/fonc.2019.01034
- Pilatova K, Bencsikova B, Demlova R, Valik D, Zdrazilova-Dubska L. Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment. Cancer Immunol Immunother. 2018 Dec;67(12):1919-1929. DOI: 10.1007/s00262-018-2166-4
SPECIALIZED EXPERTISE AND TECHNOLOGY
Research, development and manufacture of advanced therapies for academic clinical trials
GMP manufacturing and quality control
Allogeneic and autologous sources for advanced cell therapies
COLLABORATION WITH LARGE RESEARCH INFRASTRUCTURES AND RESEARCH CENTRES
Czech Clinical Research Infrastructure Research CZECRIN